Sandoz said today that the FDA has approved its Glatopa glatiramer acetate injection as a generic version of Copaxone to treat relapsing forms of multiple sclerosis.
The therapy, which is given three days per week, is administered using the Glatopaject injection device.
Get the full story at our sister site, Drug Delivery Business News.
The post Sandoz wins FDA nod for generic, injectable MS drug appeared first on MassDevice.